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OBJECTIVE — To test the hypothesis that A1C is associated with subclinical cardiovascular
disease (CVD) in a population without evident diabetes, after adjusting for traditional CVD risk
factors and BMI.
RESEARCH DESIGN AND METHODS — This was a cross-sectional study of 5,121
participants without clinically evident CVD or diabetes (fasting glucose 7.0 mmol/l or use of
diabetes medication), aged 47–86 years, enrolled in the Multi-Ethnic Study of Atherosclerosis
(MESA). Measurements included carotid intimal-medial wall thickness (CIMT) and coronary
artery calciﬁcation (CAC). Results were adjusted for age, sex, ethnicity, smoking, systolic blood
pressure, LDL cholesterol, HDL cholesterol, antihypertensive medication use, lipid-lowering
medication use, and BMI.
RESULTS — ComparedwiththoseinthelowestquartileforA1C([meanSD]5.00.2%),
participants in the highest quartile (6.0  0.3%) had higher adjusted mean values for common
CIMT (0.85 vs. 0.87 mm, P  0.003) and internal CIMT (1.01 vs. 1.08 mm, P  0.003). A1C
quartilewasnotassociatedwithprevalenceofCACintheentirecohort(P0.27);however,the
association was statistically signiﬁcant in women (adjusted prevalence of CAC in lowest and
highest A1C quartiles 37.5 vs. 43.0%, P  0.01). Among those with some CAC, higher A1C
quartile tended to be associated with higher CAC score, but the results were not statistically
signiﬁcant (adjusted P  0.11).
CONCLUSIONS — In this multiethnic cohort, there were small, positive associations be-
tween A1C, common CIMT, and internal CIMT in the absence of clinically evident diabetes. An
association between higher A1C and CAC prevalence was evident only in women.
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H
igher level of A1C, a measurement
of recent glycemia status, has been
associated with clinical cardiovas-
cular disease (CVD) in both the diabetic
andnondiabeticpopulation(1–3),butlit-
tle information is available on the associ-
ation between A1C and subclinical CVD
in nondiabetic populations. Studies of
subclinical CVD, including coronary
artery calciﬁcation (CAC) and carotid
intimal-medial wall thickness (CIMT),
can provide complementary information
to studies of clinical CVD outcomes by
providing a more focused understanding
of the factors that contribute to athero-
sclerosis, whereas studies of clinical CVD
events are also inﬂuenced by factors re-
lated to plaque rupture and thrombosis.
CACandCIMTareassociatedwithfuture
risk of CVD events (4,5) and offer an op-
portunity to better understand the factors
that contribute to the development and
natural progression of early stage CVD.
To date, the few studies that have ex-
amined the association between A1C and
subclinical CVD in individuals without
diabetes have shown mixed results.
Sander et al. (6) found that A1C was as-
sociated with progression of common
CIMT over 2 years, particularly when C-
reactive protein (CRP) was also elevated.
Doruk et al. (7) found no signiﬁcant asso-
ciation between A1C and CIMT (mean of
12 common and internal CIMT measure-
ments) in 78 elderly nondiabetic partici-
pants. Aihara et al. (8) showed that A1C
was signiﬁcantly associated with maxi-
mumplaquethickness(orCIMTifplaque
was absent) in the internal or common
carotid arteries in 306 Japanese partici-
pants; however, the association was not
independent of diabetes status and was
not described among nondiabetic partic-
ipants. Temelkova-Kurktschiev et al. (9)
showedthatfastingglucose,glucosemea-
sured 2 h after an oral glucose load (2-h
glucose), and A1C were each associated
with common CIMT in 582 German par-
ticipants without clinically diagnosed di-
abetes after adjusting for age and sex, but
30% of these participants had undiag-
nosed diabetes.
To our knowledge, there are no pub-
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the
1Department of Medicine, University of Washington, Seattle, Washington; the
2Department of
Biostatistics, University of Washington, Seattle, Washington; the
3Division of Prevention and Population
Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland; the
4Division of Epidemiology
and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota; the
5DepartmentofNutrition,UniversityofOslo,Oslo,Norway;the
6DepartmentofPathology,Universityof
Vermont, Burlington, Vermont; the
7Department of Biochemistry, University of Vermont, Burlington,
Vermont; the
8Department of Medicine, University of Vermont, Burlington, Vermont; the
9Division of
Public Health Sciences, Wake Forest University, Winston-Salem, North Carolina; the
10Department of
Internal Medicine, Wake Forest University, Winston-Salem, North Carolina; the
11Department of Epide-
miology, Johns Hopkins University, Baltimore, Maryland; the
12Department of Medicine, Johns Hopkins
University, Baltimore, Maryland; the
13Department of Medicine, Columbia University, New York, New
York; the
14Department of Epidemiology, Columbia University, New York, New York; and the
15Depart-
ment of Epidemiology, University of Washington, Seattle, Washington.
Corresponding author: Marguerite J. McNeely, mcneely@u.washington.edu.
Received 14 January 2009 and accepted 13 June 2009.
Published ahead of print at http://care.diabetesjournals.org on 23 June 2009. DOI: 10.2337/dc09-0074.
© 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Cardiovascular and Metabolic Risk
ORIGINAL ARTICLE
DIABETES CARE, VOLUME 32, NUMBER 9, SEPTEMBER 2009 1727lished studies examining the association
between A1C and CAC in participants
withoutclinicallyevidentdiabetesandno
large studies of A1C and CIMT in minor-
ity ethnic populations. The purpose of
this study was to test the hypothesis that
A1Cwithintherangeobservedinsubjects
withoutclinicallyevidentdiabetesisasso-
ciated with subclinical CVD after ac-
counting for traditional CVD risk factors
and that this association persists after fur-
ther adjustment for BMI. Secondary aims
of this study were to determine whether
theassociationbetweenA1Candsubclin-
ical CVD varied by sex or race/ethnicity
and whether results were explained by
differences in other nontraditional CVD
risk factors (triglycerides, CRP, inten-
tional exercise, and albuminuria).
RESEARCH DESIGN AND
METHODS— Details about the study
design of the Multi-Ethnic Study of Ath-
erosclerosis(MESA)havebeenpreviously
published (10). Brieﬂy, 6,814 partici-
pants, aged 45–84 years, who identiﬁed
themselves as white, African American,
Hispanic, or Asian (predominantly of
Chinese ancestry), were recruited from
six U.S. communities between July 2000
and August 2002. All participants were
free of clinically apparent CVD at enroll-
ment. Each study site recruited an ap-
proximately equal number of men and
women, according to prespeciﬁed age
andrace/ethnicityproportions.Allpartic-
ipants gave informed consent, and the
study protocol was approved by the insti-
tutional review board of each center. A1C
was measured at exam 2 in MESA, which
was conducted 16 months after the
baseline study exam. Of 6,233 participants
attending exam 2, 1,112 were excluded be-
cause of missing A1C (n  96) or fasting
glucose(n4)data,diabetesbasedonfast-
ing glucose 7.0 mmol/l (11) or reported
use of oral hypoglycemic medication or in-
sulin (n  962), or prevalent CVD at exam
2( n  50), leaving 5,121 participants for
this cross-sectional analysis.
All measurements were obtained at
exam 2, unless otherwise speciﬁed. Med-
ication use and smoking status were as-
certained by questionnaire. Smoking
status was coded as current, quit 1 year
ago,quit1yearago,andneversmoked.
Physical activity was measured by ques-
tionnaire. Participants reported the aver-
age time spent doing intentional exercise
activitiesperweekduringthepastmonth,
and the total estimated metabolic energy
expenditure (in MET units per minute)
for each activity was summed (12). The
summary scores were categorized as no
intentional exercise, 735 MET min/
week, 736–1,785 MET min/week, and
1,785 MET min/week. Fasting blood
samples were obtained for measurements
of lipids, glucose, A1C, and highly sensi-
tive CRP. CRP was not measured at exam
2, so baseline measurements were used in
the analysis. A morning urine sample was
obtained to measure urine albumin-to-
creatinine ratio, which was categorized as
normal (30 mg/g), microalbuminuric
(30–299 mg/g), or macroalbuminuric
(300 mg/g).
Common and internal CIMTs were
measured by ultrasound on all partici-
pants at baseline, as previously described
(13). CIMT was measured on the right
andleftside,andthemaximumvaluewas
used for analysis. CIMT is expected to
change only 0.008–0.012 mm per year
(14), hence we assumed that baseline
CIMT measurements were a reasonable
approximation of CIMT at exam 2.
CAC was measured using either elec-
tron-beam computed tomography at
three ﬁeld centers or multidetector com-
puted tomography at three ﬁeld centers.
Each participant was scanned twice con-
secutively, and these scans were read in-
dependently at a centralized reading
center, as previously reported (15). All
participants had CAC measured at base-
line. Follow-up CAC measurements were
performed on about half the cohort
(2,438 randomly selected participants) at
exam 2 (16 months after baseline) and
the other half of the cohort (n  2,246) at
exam 3 (39 months [range 23–59] after
baseline). For 2,246 participants who did
not have CAC measured concurrently
with A1C at exam 2, we used a linear in-
terpolationoftheirCACscoresfrombase-
line and exam 3 as an estimate of their
exam 2 CAC. Either measured or interpo-
lated CAC data for exam 2 were available
for 4,684 participants, and 437 partici-
pants had missing CAC data.
Participants who had CAC measured
at exam 2 were similar to those with in-
terpolated CAC with regard to age, sex,
smoking status, BMI, A1C, fasting glu-
cose,systolicbloodpressure,LDLcholes-
terol, HDL cholesterol, common CIMT,
and internal CIMT (all P  0.08). Com-
pared with participants with CAC mea-
sured at exam 2, participants with
interpolated CAC had higher prevalence
of detectable CAC (57 vs. 50%, 
2 test
P  0.001), lower median CAC score if
CAC 0 (66.6 vs. 85.1 Agatston units,
Wilcoxon rank sum test P  0.001), and
lower mean natural logarithm (ln) CAC
scoreifCACwasmorethanzero(3.93vs.
4.36lnAgatstonunits,Student’sttestP
0.001). Differences in CAC measure-
ments by interpolated status were not ac-
counted for by adjustment for age, sex,
race, smoking status, BMI, systolic blood
pressure, LDL cholesterol, HDL choles-
terol,antihypertensivemedicationuse,or
lipid-lowering medication use (all P 
0.001).
Statistical analysis
For CIMT, associations with A1C were
analyzed using linear regression. In the
MESA,abouthalfoftheparticipantshada
CAC score of zero, with the positive
scores being highly skewed. We modeled
this using a two-stage approach. The as-
sociation between presence or absence of
detectable CAC and A1C was analyzed
using relative risk regression (16). Specif-
ically, we used generalized linear models
with log link, Gaussian error structure
and used a Huber-White sandwich (ro-
bust)estimatorofvariancetocalculatethe
prevalence ratio (PR). Logistic regression
was not used because the presence of
CAC is not a rare outcome, and the odds
ratio would overestimate the PR. Among
those with positive CAC scores, we mod-
eled ln of the value as a function of A1C
using linear regression. Interactions be-
tween A1C and sex or A1C and race/
ethnicity were considered. To conﬁrm
that results were not dependent on A1C
outliers, we repeated all analyses exclud-
ing values 6.1% (95th percentile); re-
sults were similar, so the ﬁndings
presented in this report are based on all
available A1C data. We also modeled re-
sults using all A1C quartiles entered as
dummy variables with quartile 1 as the
reference group. These models were used
to calculate adjusted means or preva-
lences of CVD measurements by A1C
quartile using the mean value for each co-
variate. To conﬁrm that the linear inter-
polation of CAC values did not alter the
ﬁndings,werepeatedallCACanalysesus-
ingonlytheparticipantswithaCACmea-
surement at exam 2. Because multiple
comparisons were made, P values near
0.05 should be interpreted with caution.
All statistics were calculated using
Stata/SE software (version 8.0 for Win-
dows; Stata, College Station, TX).
RESULTS— Table 1 shows the char-
acteristicsofthe5,121MESAparticipants
at exam 2, stratiﬁed by A1C quartile. A1C
A1C and subclinical CVD
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percentile of 6.1% and 99th percentile of
6.6%. A1C was signiﬁcantly associated
with all characteristics except smoking
status and CAC score.
Associations of A1C and subclinical
CVD by sex and race/ethnicity
Table 2 shows the associations between
A1C (modeled as a continuous variable)
and measures of subclinical CVD, strati-
ﬁed by sex and race/ethnicity, and ad-
justed for smoking status, systolic blood
pressure, LDL cholesterol, HDL choles-
terol, antihypertensive medication use,
and lipid-lowering medication use. Re-
sults were similar after adjustment for
study site (data not shown). Higher A1C
was signiﬁcantly associated with greater
common CIMT, and there were no signif-
icant interactions by sex or race/ethnicity.
Higher A1C was signiﬁcantly associated
with greater internal CIMT, and the mag-
nitude of this association varied by race/
ethnicity but not by sex. The magnitude
oftheassociationbetweenA1Candinter-
nal CIMT was signiﬁcantly larger in
whites than in Asians (P  0.02) and His-
panics (P  0.02) but not in African
Americans (P  0.20), (P  0.04 for all
Table 1—Characteristics of nondiabetic MESA participants without clinical CVD at exam 2 by A1C quartile
Overall
A1C
quartile 1
A1C
quartile 2
A1C
quartile 3
A1C
quartile 4 Crude P
A1C range (%) (3.5–5.2) (5.3–5.4) (5.5–5.7) (5.8–8.6)
Sample size (n) 5,121 1,668 1,051 1,411 991
Age (years) 63.2  10.2 60.9  10.0 62.9  9.9 64.2  10.2 65.9  9.7 0.0001
Male sex n (column %) 2,391 (46.7) 813 (48.7) 489 (46.5) 666 (47.2) 423 (42.7) 0.03
Race/ethnicity n (column %) 0.0001
White 2,190 (42.8) 926 (55.5) 511 (48.6) 525 (37.2) 228 (23.0)
Asian American 594 (11.6) 139 (8.3) 138 (13.1) 203 (14.4) 114 (11.5)
African American 1,298 (25.4) 302 (18.1) 201 (19.1) 380 (26.9) 415 (41.9)
Hispanic 1,039 (20.3) 301 (18.1) 201 (19.1) 303 (21.5) 234 (23.6)
Smoking status n (column %) 0.85
Current 593 (11.6) 177 (10.7) 123 (11.7) 170 (12.1) 123 (12.5)
Never 2,534 (49.7) 825 (49.7) 526 (50.1) 702 (49.9) 481 (49.0)
Intentional exercise n (column %) 0.003
None 1,217 (23.8) 370 (22.2) 238 (22.7) 341 (24.2) 268 (27.1)
735 MET min/week 1,269 (24.8) 387 (23.2) 262 (25.0) 363 (25.7) 258 (26.1)
736–1785 MET min/week 1,275 (24.9) 411 (24.7) 277 (26.4) 356 (25.3) 231 (23.4)
1,785 MET min/week 1,351 (26.4) 499 (29.9) 273 (26.0) 348 (24.7) 231 (23.4)
BMI (kg/m
2) 27.9  5.2 26.9  4.8 27.2  4.9 28.2  5.3 30.0  5.6 0.0001
Systolic blood pressure (mmHg) 123  20 120  20 122  21 123  20 127  21 0.0001
LDL cholesterol (mmol/l) 2.98  0.82 2.89  0.82 3.02  0.80 3.01  0.80 3.05  0.87 0.0001
HDL cholesterol (mmol/l) 1.37  0.39 1.41  0.43 1.38  0.38 1.34  0.36 1.30  0.37 0.0001
Triglycerides (mmol/l) median
(interquartile range) 1.22 (0.87) 1.17 (0.82) 1.19 (0.83) 1.24 (0.88) 1.29 (0.89) 0.001
CRP (mg/l) median (interquartile range) 1.75 (3.21) 1.38 (2.66) 1.53 (3.04) 1.86 (3.30) 2.61 (3.98) 0.0001
A1C (%) 5.4  0.4 5.0  0.2 5.3  0.1 5.6  0.1 6.0  0.3 0.0001
Glucose (mmol/l) 5.4  0.5 5.1  0.5 5.3  0.5 5.4  0.5 5.8  0.6 0.0001
Albuminuria n (column %) 0.001
None 4,734 (93.2) 1,562 (94.3) 972 (93.0) 1,309 (93.9) 891 (90.6)
Microalbuminuria 311 (6.1) 87 (5.3) 62 (5.9) 74 (5.3) 88 (9.0)
Macroalbuminuria 33 (0.7) 7 (0.4) 11 (1.05) 11 (0.8) 4 (0.4)
Antihypertensive medication use
n (column %) 1,859 (36.3) 518 (31.1) 352 (33.5) 505 (35.8) 484 (48.8) 0.0001
Hypertension n (column %) 2,320 (45.3) 646 (38.8) 458 (43.6) 623 (44.2) 593 (59.8) 0.0001
Lipid-lowering medication use
n (column %) 983 (19.2) 240 (14.4) 185 (17.6) 300 (21.3) 258 (26.0) 0.0001
Common CIMT (mm) 0.85  0.19 0.82  0.18 0.84  0.18 0.87  0.19 0.91  0.19 0.0001
Internal CIMT (mm) 1.03  0.56 0.97  0.51 1.02  0.53 1.04  0.57 1.14  0.65 0.0001
Prevalence of CAC 0 n (column %) 2,504 (53.5) 724 (47.4) 520 (54.1) 719 (55.4) 541 (60.3) 0.0001
CAC score (if 0) (Agatston units)
median (interquartile range) 77.4 (254.2) 62.1 (217.4) 73.3 (233.2) 86.9 (273.9) 84.1 (310.7) 0.06
Data are means  SD, unless otherwise indicated. Sample size varies across A1C quartiles because of tied values. All measurements were obtained at exam 2, except
for CRP and CIMT, which were measured 16 months prior to exam 2 at baseline, and CAC, which was measured either at exam 2 (n  2,438) or interpolated from
measurements made at baseline and 39 months later at exam 3 (n  2,246). Data were missing for smoking status (n  25), intentional exercise (n  9), systolic
blood pressure (n  3), LDL cholesterol (n  42), HDL cholesterol (n  4), triglycerides (n  2), CRP (n  33), albuminuria (n  43), common CIMT (n  57),
internal CIMT (n  120), and CAC (n  437). P values for comparisons among A1C quartiles are based on 
2 or one-way ANOVA (3 degrees of freedom). For CRP,
triglycerides, and CAC score, P values were calculated using ln.
McNeely and Associates
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magnitude of the association between
A1C and prevalence of CAC score more
than zero was signiﬁcantly larger in
women than in men (P  0.001 for sex
interaction term), but there were no sig-
niﬁcant differences by race/ethnicity. For
women overall, the relative prevalence of
CACmorethanzeroincreasedby14%for
every one-unit (1%) increase in A1C
(PR1.14[1.03–1.26],P0.01).Anal-
yses restricted to the 2,438 participants
with exam 2 CAC measurements (ex-
cluding those with extrapolated CAC
measurements) showed adjusted PRs of
similarmagnitudetothoseshowninTa-
ble 2 (for all women, adjusted PR 1.12,
P  0.12; for all participants, adjusted
PR 1.06, P  0.15). Among participants
with CAC more than zero, there was no
signiﬁcant association between A1C
and CAC score in the cohort overall and
no signiﬁcant interactions by sex or
race/ethnicity.
Effect of excluding participants with
A1C >95th percentile
When participants with A1C 95th per-
centile (6.1%) were excluded, the mag-
nitude of the regression coefﬁcients or PR
were not substantially different from
those shown in Table 2 for analysis of
common CIMT in all participants (coefﬁ-
cient 0.02 [95% CI 0.01–0.03], P 
0.005), internal CIMT in all participants
(coefﬁcient 0.05 [95% CI 0.00–0.09],
P0.03),orprevalentCACinallwomen
(PR 1.14 [95% CI 1.02–1.27], P  0.02).
Effect of further adjustment for BMI
plus other nontraditional CVD risk
factors
Compared with results shown in Table 2,
results were similar when models were
further adjusted for traditional CVD risk
factors plus BMI and one of the following
variables per model: ln(triglycerides), ln-
(CRP), intentional exercise, or albumin-
uria (data not shown).
Results by quartile of A1C adjusted
for traditional CVD risk factors and
CVD risk factors plus BMI
To better demonstrate the magnitude of
the difference in subclinical CVD mea-
sures between participants across the
A1C range, adjusted means are presented
by A1C quartile in Table 3, adjusted for
traditional CVD risk factors and adjusted
for traditional CVD risk factors plus BMI.
Subgroup analyses are presented if indi-
cated by the presence of statistically sig-
niﬁcant interactions by ethnicity or sex in
Table 2. Compared with those in the low-
est quartile for A1C, participants in the
highest quartile had higher adjusted
mean values for common CIMT (0.85 vs.
0.87 mm, P  0.001) and internal CIMT
(1.01 vs. 1.08 mm, P  0.001) after ad-
justment for traditional CVD risk factors
(Table 3). For comparison, results for
lowest versus highest LDL cholesterol
quartile showed lower mean common
CIMT (0.84 vs. 0.87 mm, coefﬁcient 0.03
[95% CI 0.02–0.04], P  0.001) and
Table 2—Associations between A1C and subclinical CVD adjusted for traditional CVD risk factors
Overall
P
Women
P
Men
P
Coefﬁcient or PR
(95% CI)
Coefﬁcient or PR
(95% CI)
Coefﬁcient or PR
(95% CI)
Common CIMT (mm)
Overall 0.02 (0.01–0.04) 0.001 0.02 (0.00–0.03) 0.04 0.03 (0.01–0.05) 0.001
White 0.03 (0.01–0.05) 0.01 0.03 (0.00–0.05) 0.03 0.03 (	0.01 to 0.06) 0.14
Asian American 0.04 (0.00–0.07) 0.04 0.05 (0.00–0.10) 0.04 0.02 (	0.02 to 0.07) 0.33
African American 0.01 (	0.01 to 0.03) 0.24 	0.01 (	0.04 to 0.02) 0.54 0.03 (0.00–0.06) 0.03
Hispanic 0.03 (0.01–0.06) 0.009 0.02 (	0.01 to 0.05) 0.22 0.04 (0.01–0.08) 0.03
Internal CIMT (mm)
Overall 0.05 (0.01–0.09)* 0.01* 0.04 (	0.01 to 0.09) 0.14 0.06 (0.01–0.12) 0.03
White 0.09 (0.02–0.16) 0.01 0.09 (	0.00 to 0.18) 0.05 0.09 (	0.01 to 0.20) 0.09
Asian American 0.04 (	0.05 to 0.13) 0.38 0.06 (	0.06 to 0.19) 0.32 0.00 (	0.13 to 0.13) 0.99
African American 0.04 (	0.02 to 0.11) 0.20 0.03 (	0.07 to 0.12) 0.62 0.06 (	0.03 to 0.16) 0.18
Hispanic 0.00 (	0.07 to 0.08) 0.91 	0.03 (	0.13 to 0.06) 0.51 0.05 (	0.06 to 0.17) 0.36
Prevalence of CAC 0 (%)
Overall 1.05 (0.99–1.11)
† 0.10
† 1.14 (1.03–1.26) 0.01 1.01 (0.95–1.08) 0.71
White 1.06 (0.98–1.16) 0.14 1.20 (1.03–1.40) 0.02 1.01 (0.92–1.11) 0.79
Asian American 1.22 (1.01–1.48) 0.04 1.31 (0.94–1.82) 0.11 1.21 (0.97–1.52) 0.09
African American 1.01 (0.90–1.13) 0.93 1.16 (0.94–1.43) 0.16 0.93 (0.80–1.06) 0.28
Hispanic 1.06 (0.93–1.20) 0.39 1.02 (0.83–1.24) 0.88 1.07 (0.91–1.26) 0.38
CAC score if 0 (ln Agatston units)
Overall 0.15 (	0.03 to 0.33) 0.10 0.06 (	0.22 to 0.33) 0.70 0.22 (	0.02 to 0.45) 0.08
White 0.36 (0.07–0.65) 0.02 0.19 (	0.26 to 0.63) 0.41 0.48 (0.09–0.87) 0.02
Asian American 0.02 (	0.52 to 0.57) 0.93 	0.33 (	1.16 to 0.50) 0.43 0.31 (	0.46 to 1.08) 0.42
African American 0.01 (	0.32 to 0.34) 0.96 	0.07 (	0.61 to 0.47) 0.81 0.14 (	0.28 to 0.57) 0.51
Hispanic 0.08 (	0.33 to 0.48) 0.71 0.34 (	0.28 to 0.95) 0.28 0.04 (	0.51 to 0.59) 0.90
Partial regression coefﬁcients and PRs are for a 1% increment in A1C in separate models. Results are adjusted for age, smoking status, systolic blood pressure, LDL
cholesterol, HDL cholesterol, antihypertensive medication use, and lipid-lowering medication use. Overall models are also adjusted for sex and race/ethnicity.
Overall models were tested for interactions by race/ethnicity or sex; there were no signiﬁcant interactions except as noted. *Signiﬁcant interaction present for
association between A1C and subclinical CVD measure by race/ethnicity, P  0.05. †Signiﬁcant interaction present for the association between A1C and subclinical
CVD measure by sex, P  0.05.
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0.08 [0.04–0.13], P  0.001) after ad-
justment for traditional CVD risk factors
and A1C (continuous variable). A1C was
not signiﬁcantly associated with preva-
lence of detectable CAC in the cohort
overall,butwomeninthehighestquartile
for A1C had a higher adjusted prevalence
for detectable CAC compared with
womeninthelowestquartile(P0.003).
AmongparticipantswithdetectableCAC,
A1C was not signiﬁcantly associated with
CACscoreafteradjustmentforcovariates.
Analyses adjusted for CVD risk factors
plus BMI yielded very similar results (Ta-
ble 3).
CONCLUSIONS— In individuals
withoutclinicallyevidentdiabetes,higher
A1C level was associated with common
and internal CIMT after adjustment for
CVD risk factors and BMI. For analyses
performed on the entire cohort, A1C was
not signiﬁcantly associated with the prev-
alence of detectable CAC or with CAC
score after adjustment for covariates.
However, the association between A1C
and prevalence of detectable CAC varied
by sex: higher A1C was associated with
higher prevalence of detectable CAC in
women but not in men. Our data suggest
that glycemia within the range observed
in subjects without clinically evident dia-
betes is associated with some measures of
subclinical CVD. These ﬁndings are con-
sistent with those reported by Sander et
al. (6) for common CIMT.
To our knowledge, this is the ﬁrst
study to report on the association be-
tween A1C and CAC in people without
clinically evident diabetes. Previous re-
sults from MESA showed that the preva-
lence of detectable CAC was higher in
whites than in other ethnic groups after
adjustment for age, education, lipid levels,
BMI, smoking status, diabetes, hyperten-
sion, treatment for hypercholesterolemia,
sex, and scanning center (17). The results
of this study build on those ﬁndings, pro-
Table 3—A1C and subclinical CVD by quartile of A1C with adjustment for CVD risk factors and CVD risk factors plus BMI
A1C quartile 1 A1C quartile 2 A1C quartile 3 A1C quartile 4
Quartile 4 versus
quartile 1
P*
Mean or %
(95% CI)
Mean or %
(95% CI)
Mean or %
(95% CI)
Mean or %
(95% CI)
Coefﬁcient or PR
(95% CI)
Adjusted for CVD risk factors
Common CIMT (mm)
Overall 0.85 (0.84–0.85) 0.85 (0.84–0.86) 0.86 (0.85–0.87) 0.87 (0.86–0.89) 0.03 (0.01–0.04) 0.001
Internal CIMT (mm)
Overall 1.01 (0.98–1.03) 1.02 (0.99–1.06) 1.02 (1.00–1.05) 1.08 (1.05–1.11) 0.07 (0.03–0.12) 0.001
White 1.08 (1.05–1.12) 1.06 (1.02–1.11) 1.11 (1.07–1.16) 1.21 (1.14–1.28) 0.13 (0.05–0.21) 0.002
Asian American 0.79 (0.73–0.85) 0.83 (0.77–0.89) 0.79 (0.73–0.84) 0.86 (0.79–0.93) 0.07 (	0.03 to 0.17) 0.17
African American 1.02 (0.96–1.09) 1.08 (1.00–1.16) 1.04 (0.99–1.10) 1.10 (1.04–1.15) 0.08 (	0.01 to 0.16) 0.08
Hispanic 0.96 (0.90–1.01) 1.00 (0.93–1.06) 0.94 (0.89–1.00) 0.97 (0.91–1.04) 0.02 (	0.07 to 0.10) 0.72
Prevalence of CAC 0 (%)
Overall 49.0 (47.0–51.1) 50.9 (48.1–53.1) 50.9 (48.8–53.0) 51.7 (49.2–54.4) 1.06 (0.99–1.12) 0.09
Women 37.3 (34.4–40.3) 40.1 (36.8–43.7) 40.6 (37.7–43.7) 43.5 (40.3–47.1) 1.17 (1.05–1.30) 0.003
Men 62.1 (59.1–65.1) 62.5 (59.0–66.2) 62.4 (59.4–65.5) 62.3 (58.5–66.5) 1.00 (0.93–1.08) 0.92
CAC score if 0 (ln
Agatston units)
Overall 4.04 (3.90–4.17) 4.05 (3.90–4.21) 4.21 (4.08–4.34) 4.25 (4.09–4.41) 0.21 (	0.00 to 0.42) 0.05
Adjusted for CVD risk factors
and BMI
Common CIMT (mm)
Overall 0.85 (0.84–0.86) 0.85 (0.84–0.86) 0.86 (0.85–0.87) 0.87 (0.86–0.88) 0.02 (0.01–0.02) 0.003
Internal CIMT (mm)
Overall 1.01 (0.98–1.03) 1.03 (0.99–1.06) 1.02 (0.99–1.05) 1.08 (1.04–1.11) 0.07 (0.02–0.11) 0.003
White 1.08 (1.05–1.12) 1.06 (1.02–1.11) 1.11 (1.07–1.16) 1.21 (1.14–1.28) 0.13 (0.04–0.21) 0.003
Asian American 0.79 (0.73–0.85) 0.83 (0.77–0.89) 0.79 (0.73–0.84) 0.86 (0.78–0.93) 0.07 (	0.03 to 0.12) 0.18
African American 1.02 (0.95–1.08) 1.08 (1.00–1.16) 1.05 (0.99–1.10) 1.10 (1.05–1.16) 0.08 (	0.01 to 0.17) 0.07
Hispanic 0.96 (0.91–1.02) 1.00 (0.94–1.07) 0.94 (0.89–0.99) 0.96 (0.90–1.03) 0.00 (	0.09 to 0.09) 0.36
Prevalence of CAC 0 (%)
Overall 49.3 (47.2–51.4) 50.6 (48.3–53.2) 50.7 (48.6–52.9) 51.0 (48.5–53.7) 1.04 (0.97–1.10) 0.27
Women 37.5 (34.7–40.5) 40.3 (36.7–43.9) 40.5 (37.6–43.5) 43.0 (39.7–46.5) 1.15 (1.03–1.30) 0.01
Men 62.4 (59.4–65.4) 62.6 (59.2–66.4) 62.2 (59.2–65.3) 61.6 (57.8–65.7) 0.99 (0.92–1.07) 0.77
CAC score if 0 (ln
Agatston units)
Overall 4.05 (3.92–4.19) 4.06 (3.91–4.22) 4.21 (4.08–4.34) 4.23 (4.07–4.39) 0.18 (	0.04 to 0.39) 0.11
CVD risk factors: age, sex, smoking status, systolic blood pressure, LDL cholesterol, HDL cholesterol, antihypertensive medication use, and lipid-lowering
medication use. In addition to overall results for the entire cohort, subgroup analyses based on separate models are presented if indicated by the presence of
statistically signiﬁcant interactions by race/ethnicity or sex as shown in Table 2. *P values compare fourth and ﬁrst quartiles.
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out clinically evident diabetes who have
detectable CAC the magnitude of the cor-
relation between A1C and CAC score
tended to be larger in whites than Asians,
African Americans, and Hispanics; how-
ever, the analysis for interaction by race
did not reach statistical signiﬁcance. We
are not aware of other studies that exam-
ined whether the association between
A1CandclinicalCVDriskinpeoplewith-
out clinically evident diabetes varied by
race/ethnicity. However other studies
have shown that whites with diabetes
have higher CVD incidence than Asian
Americans, African Americans, and Lati-
nos(18).Thus,itispossiblethatglycemia
is a stronger clinical CVD risk factor in
whites than in other ethnic/racial groups,
butfurtherstudyisneededinpopulations
without clinically evident diabetes.
We found that the prevalence of de-
tectable CAC was associated with A1C in
women but not in men. The explanation
for this observation remains unclear.
However, our results are consistent with
thosefromtheFraminghamStudy,where
impaired fasting glucose was associated
with 4-year CVD incidence in women but
not in men (19). Thus, mild hyperglyce-
mia (associated with fasting glucose 7.0
mmol/l) may increase the relative risk of
CVD to a greater extent in women than
men.
CAC and CIMT are two distinct
markers of subclinical CVD. The associa-
tion between A1C and subclinical CVD
varied in our data depending on whether
CIMT or CAC was used as the outcome.
These differences might be due to differ-
ences in measurement accuracy between
CIMT and CAC or differences in the asso-
ciationbetweenA1CandsubclinicalCVD
by anatomic site of atherosclerosis. It
should also be noted that there was less
statistical power to detect associations
with CAC score because only about half
the participants had detectable CAC.
The current use of a fasting glucose
level 7.0 mmol/l to deﬁne diabetes is
based largely on data that support the
concept of a hyperglycemic threshold be-
low which microvascular diabetic com-
plications are unlikely to occur (11).
However, others have concluded that this
concept of a hyperglycemic threshold
does not appear to apply to CVD (macro-
vascular disease) risk (20). The results of
this study were limited to participants
without clinically diagnosed diabetes
whose fasting glucose was less than the
value used to deﬁne diabetes. Thus, our
ﬁndings suggest either that the associa-
tion between hyperglycemia as measured
by A1C and subclinical macrovascular
disease is continuous (i.e., no threshold
effect) or that the A1C threshold for ma-
crovascular disease complications of hy-
perglycemia is within the range of values
observed in people whose fasting glucose
level is below the diagnostic threshold for
diabetes.Weobtainedsimilarresultseven
when we excluded participants whose
A1C was 95th percentile (6.1%), so if
there is a threshold it appears to occur at
lower values of A1C. The magnitude of the
differences in CIMT across quartiles of A1C
was similar to that of the differences in
CIMT across quartiles of LDL cholesterol.
Whilewedidnotﬁndanyevidenceto
support a diagnosis of diabetes in the 5%
ofparticipantswithA1C6.1%basedon
fasting glucose level or medication use, it
is likely that some participants in this
study may have met criteria for diabetes
by an oral glucose tolerance test. About
2.6% of adults 20 years of age with fast-
ing glucose in the nondiabetic range have
undiagnosed diabetes based on 2-h glu-
cose (21). However, the diagnostic crite-
ria used in our study are those most
commonly used in clinical practice in the
U.S. (11). Furthermore, because results
were similar when participants with A1C
6.1% were excluded, it is unlikely that
our results were due to misclassiﬁcation
of diabetes status. We did not screen par-
ticipants for genetic hemoglobin variants,
which may be another potential explana-
tion for A1C levels that did not correlate
as expected with fasting blood glucose
levels.
Ourresultsareconsistentwiththere-
sults of other studies that showed an as-
sociationbetweenglucoseandsubclinical
CVD in nondiabetic populations. Zhang
et al. (22) found that 2-h glucose was as-
sociatedwithcommonCIMTafteradjust-
mentforage,LDLcholesterol,andinsulin
sensitivity.TheRIAD(RiskFactorsinIGT
for Atherosclerosis and Diabetes) study
showed that 2-h glucose was associated
with common CIMT in nondiabetic sub-
jects after adjustment for age, sex, total
cholesterol, HDL cholesterol, triglycer-
ides, and C-peptide (23). Our study ad-
vances the understanding of the
association between glycemia and sub-
clinical CVD by demonstrating that A1C
was associated with common CIMT and
internal CIMT in participants from four
racial/ethnicgroups.Also,weusedA1C,a
measure of overall glycemia, not just fast-
ing or postprandial glycemia (20).
There are several limitations to this
study. CIMT measures were obtained
16 months prior to the A1C measure-
ments. Others (14) have demonstrated
thatlittlechangeinCIMTisexpectedover
this interval. Any change in A1C values
between baseline and exam 2 might
weaken the correlation between A1C
measuredatvisit2andCIMTmeasuredat
baseline, but we know of no reason to
expectthatthiswouldincreasethechance
of a spurious association. CAC measure-
ments were obtained at exam 2 (simulta-
neous with the A1C measurement) in
52% of participants, and missing CAC
data for exam 2 were interpolated from
baseline and exam 3 CAC measurements.
This approach is unlikely to have intro-
duced systematic bias, as shown by the
similar results obtained from analyses re-
stricted to the subset of participants with
exam 2 CAC data.
In summary, in this multiethnic co-
hort, there were small, positive associa-
tions between A1C, common CIMT, and
internal CIMT in the absence of clinically
evident diabetes. The associations be-
tween A1C and CIMT were not fully ex-
plained by adjustment for traditional
CVD risk factors or BMI. An association
between increased A1C and CAC preva-
lence was evident only in women. These
ﬁndings suggest that a clinical deﬁnition
of diabetes based on fasting glucose does
not completely capture the CVD risk that
is associated with variation in glycemia as
measured by A1C.
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